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Abstract
Background: Hepatitis B virus (HBV) exists in the breast milk of chronic hepatitis B (CHB) mothers. The authors use
a meta-analytic technique to quantify the evidence of an association between breastfeeding and risk of CHB
infection among the infants vaccinated against HBV.
Methods: Literature search is performed up to 2010 on the relationship between infantile CHB infection within
one-year follow up after immunization with the third-dose hepatitis B vaccine and breastfeeding. Two reviewers
independently extract the data and evaluate the methodological quality. A random-effects model is employed to
systematically combine the results of all included studies.
Results: Based on data from 32 studies, 4.32% (244/5650) of infants born of CHB mothers develop CHB infection.
The difference in risk of the infection between breastfed and formula-fed infants (RD) is -0.8%, (95% confidence
interval [CI]: -1.6%, 0.1%). Analysis of the data from 16 of the studies finds that RD for mothers who are positive for
the HBeAg and/or the HBV DNA, 0.7% (95%CI: -2.0%, 3.5%), is similar to that for those who are negative for these
infectivity markers, -0.5% (95%CI: -1.7%, 0.6%).
Conclusions: Breast milk is infectious; yet, breastfeeding, even by mothers with high infectivity, is not associated
with demonstrable risk of infantile CHB infection, provided that the infants have been vaccinated against HBV at
birth.
Background
The hepatitis B virus (HBV) accounts for a significant
morbidity and mortality worldwide. An estimated one-
third of the world population has been exposed to HBV
and 400 million people are chronic carriers [1]. Mother
to infant transmission of HBV would occur among up to
90% of infants born of chronic hepatitis B (CHB) mothers
who are positive for the infectivity markers, the HBeAg
and/or the HBV DNA [2]. With the introduction of a
safe and effective hepatitis B vaccine, infantile CHB infec-
tion has dramatically dropped to around 5% [3].
The advantages of breastfeeding over formula feeding
have been well documented [4]. However, the presence
of the HBV in breast milk firstly reported by Linnemann
[5] in 1974 and confirmed by later studies [6,7] raised
the possibility of transmission of HBV through breast-
feeding. But later studies found no association between
breastfeeding and infantile CHB infection, both before
and after the introduction of hepatitis B vaccine [8-13].
In the absence of evidence that breastfeeding poses any
additional risk of infection to infants born of CHB
mothers, World Health Organization (WHO) recom-
mends breastfeeding even for area where HBV infection
is highly endemic and HBV vaccine is not available [14].
Scepticism about this recommendation remains
among clinicians, however. About 25% of obstetricians
in Australia [15] and 50% of physicians (most of them
were hepatologists!) in Illinois [16] did not recommend
CHB mothers to breastfeed their babies. It was noted
that 5.4% of pregnant women in Shanghai were HBsAg
positive and 30.3% of whom were HBeAg-positive (Tao,
personal communication), which was reported to pose a
significant risk of HBV transmission to infants, including
those who had been vaccinated against the virus [17]. In
the light of this and other studies [10], it is a common
and recommended practice that CHB mothers with an
abnormal alanine aminotransferase (ALT) level before
delivery do not breastfeed.
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assess the risk of CHB infection of vaccinated infants
through breastfeeding associating with CHB mothers
who are and are not positive for the HBV infectivity
markers.
Methods
Data sources and search strategy
Two independent investigators (Ye and Zhou) searched
PubMed (1966-), Chinese BioMedical Literature data-
base (CBM, 1978-), Chinese National Knowledge Infra-
structure (CNKI, 1979-) and Wanfang Data (Wanfang,
1998-) up to December 31
th, 2010 by using the combi-
nation of MeSH terms “breast feeding” or “breastfeed-
ing” and “hepatitis B”. In addition, the reference lists of
potentially relevant manuscripts were scanned backward
to obtain extra eligible studies.
Criteria for inclusion of the studies
(1) Follow-up studies, prospective or retrospective, on
the association between breastfeeding (BF) versus for-
mula-feeding (FF) and risk of CHB infection among the
infants born of CHB mothers.
(2) All infants must receive at least 3 doses of hepatitis
B vaccines, with or without receiving hepatitis B immu-
noglobulin (HBIG) after birth.
(3) CHB infection is defined as the presence of any of
the three HBV markers (HBsAg, HBeAg and HBV
DNA) in blood, during prenatal care visit and/or before
delivery of their babies for the mothers and within one
year after immunization with the third-dose hepatitis B
vaccine for the infants.
Data extraction
Two independent investigators (Xia and Yao) were
involved in data extraction. The third investigator (Lu)
examined the results, and a consensus was reached. The
o u t c o m e ,C H Bi n f e c t i o no ft h ei n f a n t sb o r no fC H B
mothers at the end of follow-up within one year after
immunization with the third-dose hepatitis B vaccine
was considered. We extracted the following data from
the eligible studies: authors’ names, journal and year of
publication, country of origin, enrolment periods, type
of study, number of CHB and non-CHB among the
infants by feeding methods, general characteristics of
the babies and their mothers.
Assessment of methodological quality
Two independent investigators (Yao and Wei) evaluated
the quality of each study based on Newcastle-Ottawa
Quality Assessment Scale (NOS) [18]. The third investi-
gator (Zheng) examined the results, and a consensus
was reached (Table 1). We did not consider the 4
th item
under selection (Demonstration that outcome of interest
was not present at start of study) and the 2
nd item
under outcome (Was follow-up long enough for out-
comes to occur) in NOS, for the reason that the out-
comes were available at the end of the follow-up period
which was pre-defined in our criteria of inclusion. And
we defined the studies with NOS ≥ 5a sw i t hh i g hq u a l -
ity and the others with NOS < 5 as with low quality.
Statistical analysis
The risk difference (RD) with 95% confidence interval
(CI) was used as a measure of effect between breastfeed-
ing (BF) versus formula-feeding (FF) and risk of infantile
CHB infection across studies. The Dersimonian and
Laird random-effects model was used to pool the RDs
across studies in Stata version 10.0 (Stata Corp). Hetero-
geneity was explored by c
2 test, with a significance set at
a P value < 0.10. The extent of heterogeneity was mea-
sured by Higgins’ I
2. Subgroup analysis and Meta-regres-
sion were carried out to examine the effect in relation to
quality and type of study, language of paper, study sites,
hepatitis B vaccination of the mothers and infants, and
mothers’ infectivity if available. We used the test for
interaction to estimate the difference between two sub-
groups [19]. Publication bias was assessed by visual
inspection of a funnel plot, the Egger’s and Begger’st e s t
[20], and a nonparametric trim and fill method was per-
formed [21].
Results
1. Literature search
The search retrieved 517 papers, and 99 out of which
were potentially relevant to current analysis. Further
backward search produced 3 additional papers. Only 32
papers [7,10-13,22-48] which offered 32 independent
studies were included in our analysis and the reasons
for exclusion of the others were listed in Additional file
1-Figure S1.
2. General characteristics about the studies included in
meta analysis
The 32 studies included in present analysis were pub-
lished between 1985 and 2010 (Table 1). One study was
conducted in the United States [10], one in Italy [11]
and the other 30 in China, including Hongkong.
Mothers decided the feeding methods in all studies
except one in which they were randomized [38]. The
sample size of the studies ranged from 38 to 436 (med-
ian, 143), with the ratio of BF versus FF infants of 0.09-
5.07 (median, 0.94).
3. The risk difference (RD) of infantile CHB infection with
methods of feeding
The 32 studies contributed 5650 infants and 244 CHB
outcomes with an overall transmission rate of 4.32%.
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No Author,
publication
year and
NOS
Mothers
enrolled
period and
sites
Number of
infants,
length of
follow up
and types
of study
Characteristic
of the
mothers*
1
Mothers’
Infectivity
%
Characteristic
of the babies
Infantile
vaccination*
2
DBF
(m)
Other characteristics
1. De Martino
[11]
1985
3
NA
Italy
85 cases
12 months
Prospective
APCW, S+ and
C+; a normal
pregnancy;
informed
consent.
2.3(E) Normal ALT
and birth
weight.
0.5 ml/kg
HBIG/8 h + 1
ml(P)/2-4-11
m
Sex ratio of 1.2, no
medication except a
multivitamin mixture,
vaccination against polio,
tetanus and diphtheria;
monthly visit, no dropout; no
vaccine-related serious side
effect and no abnormal ALT
was observed at the end of
follow up.
Mothers’ E+% and newborns’
gender were similar between
BF and FF.
2. Tseng [12]
1988
3
NA
Hongkong,
China
170 cases
12 months
Retrospective
PCW, S+. 64(E)
among BF
0.5 ml HBIG/
24 h + 5 μg
(P)/0-1-6 m
3. Huang [22]
1993
3
Aug. 1989-
Sept. 1990
Guangdong,
China
112 cases
12 months
Retrospective
PCW, S+. 44.8(E) S+% = 6.4 and
E+% = 25.6 (U)
at birth.
30 μg(P)/0-1-6
m
9-12 Average age of the mothers
was 26.97 ± 2.83 years old.
4. Wu [23]
1996
3
1992-1993
Nanjing,
China
80 cases
6 months
Retrospective
PCW, S+. 55.6(E)
among BF
Full-term
normal delivery.
200IU HBIG/4
h,1 m +30 μg
(P)/1-3-6 m.
12 Mothers’ age were similar
between BF and FF.
5. Zeng [24]
2001
4
Jan. 1996-
Jun. 1999
Guangdong,
China
190 cases
9 months
Retrospective
PCW, S+;
normal ALT.
29.5(E) S+% = 14.9(U,
134cases) at
birth.
10 μg (R)/0-1-
6m
Mothers’ E+% was higher in
FF than BF.
6. Wu [25]
2002
3
Jan. 1995-
Dec. 2000
Nanjing,
China
300 cases
12 months
Retrospective
PCW, S+;
normal hepatic
function; no
nipple crack;
200IU-HBIG
treatment.
100 (E) Complete
gestation birth;
no oral ulcer.
200IU HBIG/4
h,1 m+10 μg
(R)/1-3-6 m
with booster.
11 Mothers’ age range was 25-31
years.
7. Hill [10]
2002
6
Jan. 1992-
Sept. 1998
Texas, The
United
States
369 cases
9-15 months
Prospective
PCW, S+, CG+
and CM-
24.5(E, 179
cases)
0.5 ml HBIG+
0-1-6 mwith
booster.
4.9 Complete follow-up and
vaccination; mothers’
nulliparous% (all cases), AST/
ALT level, anti-HCV+%, HIV-1+
%, E+%, CG+% and CM+%
based on available cases, and
newborns’ gender were
similar between BF and FF.
Mothers were younger and
with more blacks in FF than
BF.
8. Wang [13]
2003
5
1994-1999
Shanghai,
China
230 cases
12 months
Retrospective
APCW, S+;
normal ALT.
34(E) 37-42 gestation
weeks; S+% =
10.9 at birth.
30 μg(P,
before 1997)
or 5 μg(R,
after 1997)/0-
1-6 m or/24 h
+1-2-7 m
≥ 2 Those infants were excluded
with an obvious abnormality,
birth weight < 2500 g, or an
apgar score of < 8 at 1 or 5
minutes.
Mothers’ E+%, newborns’
gender, birth weight and S+%
at birth were similar between
BF and FF.
BF group received more
active immunization than FF.
9. Zeng [26]
2003
2
May 1995-
Sept. 1997
Sichuang,
China
53 cases
12 months
Retrospective
PCW, S+. 100(E or
DNA)
S-at birth. 200IU HBIG/
24 h+30 μg
(P)/2 w,10 μg/
1.5 m, 10 μg/
6.5 m
≥ 4 Duration of breastfeeding < 4
months was excluded.
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10. Gu [27]
2003
3
1998-1999
Nanjing,
China
152 cases
12 months
Prospective
PCW, S+ and c
+; 200~400IU-
HBIG
treatment
0(E) Healthy;
complete
gestation
weeks; birth
weight > 3000
g; S+% = 7.6 at
birth.
10 μg(R, 80
cases) or 30
μg (P, 72
cases)/24 h-1-
6m
Proportion of types of
vaccines was similar between
BF and FF.
11. He [28]
2004
3
Dec. 1997-
Dec. 1999
Inner
Mongolia,
China
38 cases
12 months
Retrospective
PCW, S+. 100(DNA) DNA+% = 56
(U)
100-200IU
HBIG/6 h, 2 w
+ 0-1-6 m
12. Liu [29]
2004
3
Feb. 1998-
Feb. 2001
Henan,
China
436 cases
12 months
Retrospective
APCW, S+;
200IU-HBIG
treatment.
S+% = 8.7 and
E+% = 0.9 at
birth
200IU HBIG/
24 h, 2 w+5
μg(R)/0-1-6 m
Newborns’ S+% and E+% at
birth were similar between BF
and FF.
13. Yao [30]
2004
4
Dec. 2000-
Jun. 2002
Zhejiang,
China
190 cases
12 months
Retrospective
PCW, S+;
200IU-HBIG
treatment.
72.9(E) Healthy;
complete
gestation
weeks; DNA+%
= 5.0 and S+%
= 6.3 at birth.
200IU HBIG/6-
12 h,2 w+5
μg(R)/0-1-6 m
Mothers’ age, uterine
contraction+%, duration of
uterine contraction, E+% and
HBV+%, and newborns’
gestation weeks and birth
weight were similar between
BF and FF.
14. Meng [31]
2004
4
Mar. 2001-
Mar. 2003
Guangdong,
China
134 cases
6 months
Prospective
PCW, S+;
normal ALT;
200IU-HBIG
treatment (66
cases).
S+% = 16.4, E+
% = 6.7 and
DNA+% = 2.2
at birth.
0-1-6 m No foetus abnormality, no
history of treatment of anti-
virus drugs during pregnancy,
TORCH syndrome and other
diseases.
15. Mou [32]
2005
5
Sept. 2001-
Oct. 2003
Shandong,
China
91 cases
12 months
Prospective
PCW, S+;
normal hepatic
function;
informed
consent.
33.0(E)
37.4(DNA)
DNA+% = 13.2
(U) at birth.
200IU HBIG/
12 h,2 w+0-1-
6 m with
booster.
≥ 1 Exclusion for those with
premature birth, low birth
weight, asphyxia and history
of bleeding during
pregnancy, breastfeed < 1
month.
Mothers’ E+% and DNA+%,
newborns’ gestation weeks,
birth weight and DNA+% (U)
were similar between BF and
FF.
16. Zhang [33]
2005
4
2000-2004
Ningxia,
China
104 cases
12 months
Prospective
PCW, S+;
200IU-HBIG
treatment.
100(E) 200IU HBIG/
24 h, 1 m+10
μg(R)/2-3-6 m
Natural delivery% = 50.0
17. Zhang [34]
2005
3
Jan. 2001-
Feb. 2002
Chongqing,
China
67 cases
12-18
months
Retrospective
PCW, S+;
100IU-HBIG
treatment.
28.4(E) 200IU HBIG/
24 h+100IU
HBIG/15d+10
μg(R)/2-3-6 m
Mothers’ E+% was higher in
FF than BF.
18. Qiu [35]
2005
3
Dec. 2002-
Mar. 2004
Zhejiang,
China
90 cases
6 months
Retrospective
PCW, S+;
normal hepatic
function; no
nipple crack;
200IU-HBIG
treatment.
100(E) Healthy;
complete
gestation
weeks.
200IU HBIG/6
h+5 μg (R)/12
h-1-6 m
> 6 Mothers’ age and DNA+%,
newborns’ gestation weeks
were similar between BF and
FF.
19. Zeng [36]
2006
4
Jun. 2001-
Dec. 2003
Guangxi,
China
115 cases
7 months
Prospective
PCW, S+;
normal ALT;
200IU-HBIG
treatment.
31.3(E) Apgar > 7;
birth weight >
2500 g; S+% =
12.2 at birth.
200IU HBIG/
24 h, 1 m+ 5
μg (R)/72 h-1-
6m
>
0.5
Mothers’ E+%, newborns’
gender, birth weight and HBV
+% at birth were similar
between BF and FF.
20. Ma [7]
2006
4
1993-1999
Liaoning,
China
167 cases
9 months
Retrospective
PCW, S+. 54(E) Birth
temperature <
37°C; birth
weight > 2500
g; apgar > 8.
(R)/0-1-6 m Mothers’ E+% was similar
between BF and FF.
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21. Chen [37]
2006
4
Mar. 2002-
May. 2005
Zhejiang,
China
170 cases
12 months
Retrospective
APCW, S+;
normal hepatic
function;
informed
consent.
41.2(E) DNA+% = 9.4
(U).
200IU HBIG/
12 h,14 d+5
μg(R)/0-1 -6
m with
booster
≥ 1 Exclusion for those with
premature birth, low birth
weight, asphyxia and history
of bleeding during
pregnancy, breastfeeding
below one month.
Mothers’ E+% and DNA+%,
newborns’ birth weight,
gestation weeks and DNA+%
were similar between BF and
FF.
22. Zuo [38]
2007
4
May 2004-
May 2005
Hebei, China
180 cases
12 months
prospective
PCW, S+;
200IU-HBIG
treatment.
49.4(E) S+% = 6.7 and
DNA+% = 4.2
at birth.
200IU HBIG/
48 h,1 m,3 m
+5 μg(R)/24
h-1 -6 m
10 The infants were randomized
into two groups.
Mothers’ age, E+% and DNA+
%, newborns’ birth weight,
method of delivery, S+% and
DNA+% were similar between
BF and FF.
23. Wang [39]
2007
3
Oct. 2003-
Jan. 2006
Ningxia,
China
165 cases
10-12
months
Retrospective
APCW, S+. 0(E) S+% = 11.5
and E+% = 2.4.
200IU HBIG/6
h+5 μg(R)/2
d-1-6 m
Mothers’ age and DNA level,
newborns’ sex ratio, birth
weight and method of
delivery were similar between
BF and FF.
24. Qin [40]
2007
3
Jan. 2001-
Jan. 2005
Henan,
China
74 cases
12 months
Retrospective
PCW, DNA+;
200IU-HBIG
treatment.
100(DNA) DNA+% = 4.5
at birth
200IU HBIG/
16 h+10 μg
(R)/1-2-7 m or
10 μg(R)/0-1-6
m
25. Chen [41]
2008
4
Oct. 2002-
Aug. 2007
Beijing,
China
345 cases
12 months
Retrospective
PCW, S+. 0(E and
DNA)
10 μg(R)/0-1-6
m+ 100-200IU
HBIG/24 h,
15-30d(241
cases).
Proportion of infants who
received HBIG was higher in
FF than BF.
26. Hou [42]
2009
4
Jan. 2002-NA
Shenzhen,
China
369 cases
9-15 months
Retrospective
PCW, S+;
abnormal ALT/
AST% = 2.2.
13.6(E) 100IU HBIG/1
d+5 μg(R)/0-
1-6 m with
booster.
4.9 Mothers’ age, abnormal ALT/
AST%, E+%, CM+% and CG+
%, newborns’ sex ratio were
similar between BF and FF.
27. Li [43]
2009
2
2004-2007
Shandong,
China
45 cases
12 months
Retrospective
APCW, S+;
normal hepatic
function;
200IU-HBIG
treatment.
33.3(E) DNA+% = 10.0
at birth.
200 IU HBIG/
12 h, 2 w+ 0-
1-6 m with
booster.
Mothers’ E+% and DNA+%,
newborns’ gestation weeks,
birth weight and DNA+%
were similar between BF and
FF.
28. Luo [44]
2010
4
2007-2009
Fujian, China
436 cases
6 months
retrospective
PCW, S+;
normal hepatic
function;
200IU-HBIG
treatment.
44.0(E) 200 IU HBIG/
12 h, 2 w+5
μg(R)/0-1-6 m
> 6 Mothers’ E+% and DNA+%
were higher in FF than BF.
29. Chen [45]
2010
3
2001-2009
Shandong,
China
278 cases
8-12 months
Retrospective
PCW, S+;
200IU-HBIG
voluntary
treatment.
200IU HBIG/
24 h,2 w or
200IU HBIG/
24 h +0-1-6
m or 0-1-2-7
m
Mothers’ age range was 21-40
years old.
30. Sun [46]
2010
2
Nov. 2007-
Jul. 2008
Shandong,
China
69 cases
12 months
retrospective
PCW, S+. DNA-at birth HBIG+(R)/0-1-
6m
31. Liu [47]
2010
4
Jan. 2009-
Mar. 2010
Guangdong,
China
145 cases
12 months
retrospective
PCW, S+;
200IU-HBIG
treatment.
58.1(DNA) 200IU HBIG+5
μg (R)/0-1-6
m
> 6 Mothers’ DNA+%, age, time
of pregnancy and delivery,
methods of delivery,
newborns’ birth weight, S+%
and DNA+% at birth were
similar between BF and FF.
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Page 5 of 10The difference between the risk of infantile CHB infec-
tion among BF and FF infants (RD) determined by the
random-effects model was -0.8%, (95% confidence inter-
val [CI]: -1.6%, 0.1%) (Figure 1) and that determined by
t h ef i x e d - e f f e c t sm o d e lw a s- 0 . 4 %( 9 5 %C I :- 1 . 6 % ,0 . 7 % ) .
The findings suggest that BF is not associated with
additional risk of infantile CHB infection concurred
with that of all the individual studies, except one [11],
which suggests that BF is associated with a lower risk
than FF.
Subgroup studies showed that the RDs could be modi-
fied by language of paper and quality of study, but not
Table 1 General characteristic and quality score of the 32 studies included in this meta analysis (Continued)
32. Wu [48]
2010
3
Sept. 2007-
May. 2009
Guangdong,
China
46 cases
12 months
Retrospective
PCW, S+. 100 (both
E and
DNA)
200IU HBIG/6
h+5 μg(R)/0-
1-6 m
Mothers’ age, newborns’ sex
ratio, birth weight and
methods of delivery were
similar between BF and FF.
NOS: Newcastle-Ottawa Quality Assessment Scale; NA: not available; BF: breastfeeding; FF: formula feeding; hepatitis B immunoglobulin: HBIG; APCW:
asymptomatic prenatal care women; PCW: prenatal care women; S: HBsAg; E: HBeAg; C: HBcAb; CG: HBcAb IgG; CM: HBcAb IgM; DNA: HBV DNA; P: plasma-
derived vaccine; R: recombinant vaccine; U: umbilical cord blood; ALT: alanine aminotransferase; AST: aspartate aminotransferase; IU: international unit; m: month;
w: week; d: day; h: hours; ml: millilitre; kg: kilogram; μg: microgram; DBF: duration of breastfeeding
*
1: HBIG treatment: HBIG was received by the mothers at the gestation weeks of 28 th, 32 th and 36 th each.
*
2: One boost dose was given to those infants with negative HBsAb status.
Figure 1 Effect of breastfeeding on occurrence of chronic hepatitis B (CHB) infection among the infants born of CHB mothers
analyzed by a random-effects model. RD: risk difference; CI: confidence interval; CHB: chronic hepatitis B.
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tion. The studies in English or with high quality tended
to report lower RDs, which would probably reflect the
difference of mothers’ HBV infectivity (Table 2).
Data on HBV infectivity available from 16 of the 32
studies showed that 42.0% (1648/3924) of mothers were
designated with “high infectivity”,b e i n gp o s i t i v ef o r
either the HBeAg and/or the HBV DNA, and that the
proportion of these mothers was lower among those who
elected to BF (36.9%, 739/2001) than those who elected
to FF (44.1%, 812/1843) (Table 2). The overall RD was
-0.4% (95% CI: -1.4%, 0.7%), which was not modified by
language of paper, quality and type of study, study sites
or infant-mother vaccination by both subgroup analysis
and Meta regression. And the RD determined for
mothers with high infectivity was 0.7% (95% CI: -2.0%,
3.5%), which was not significantly different (Z = 0.789, P
> 0.05) from that determined for mothers with low infec-
tivity, -0.5% (95% CI: -1.7%, 0.6%) (Figure 2).
4. Publication bias and its correction
Visual inspection of the funnel plots demonstrated a
possible publication bias. After trim and fill methods
were performed, the pooled RDs were -1.0% (95%CI:
-1.8%, -0.1%) and -0.6% (95%CI: -1.6%, 0.5%) respec-
tively for the 32 and 16 studies (Figure 3, 4).
Discussion
Our results suggest that breastfeeding by CHB mothers
does not pose a significant risk of infection by the virus,
provided that the infants have been vaccinated against
HBV at birth.
In this meta analysis, the overall transmission rate of
HBV from CHB mothers to their infants who had com-
pleted routine hepatitis B vaccination was 4.32%, which
was similar to those previously reported [3]. Mother-to-
infant transmission of HBV can occur prenatally, at
birth and postnatally [49], but most commonly infection
occurs at the time of delivery. In-utero transmission is
very uncommon, except in China and Japan, and often
persists after birth, which results in the ineffectiveness
of HBV vaccination, i.e., immunoprophylaxis [49,50].
From this perspective, most mother-to-infant transmis-
sion occurs before deciding on infant feeding methods.
But there is an exception: the neonate can be infected
postnatally by household contact with CHB family
members [51]. Apparently, breastfeeding would produce
more frequent contacts between mother and infant than
formula-feeding. Though separation of breastfed trans-
mission of CHB from contact seems to be important in
the clarification of the net effect of breastfeeding on
infantile CHB infection, this contact transmission occurs
only at the successful exchange of body fluid from
infected mothers to their infants under some special
situations, such as excoriation. Thus breastfed transmis-
sion of HBV, if existed, should be minimal.
Two previous meta analyses reported different associa-
tions of breastfeeding and infantile CHB infection with
an odds ratio (OR) = 1.68 (95%CI: 1.16, 2.44) [52] and
0.67 (95%CI: 0.41, 1.12) [53] respectively based on 13
and 10 studies. The inconsistent results reflected differ-
ence between the studies with respect to their study
aim, search strategies, criteria of inclusion and exclusion
of the studies, and analysis strategies. One study
included both vaccinated and not vaccinated infants [52]
and the other included only those who had been given
both passive and active immunization [53]. After careful
evaluation on these two analyses, we identified their
obvious shortcomings: (1) many eligible studies were
not included in these analyses without any reason; (2)
the analyses excluded those studies with zero outcome
of infantile CHB infection in both groups of feeding
methods; (3) neither of the studies evaluated the quality
of the included studies and their influence on the
results, and (4) neither of the studies considered the
possible confounding of mothers’ infectivity, which was
important in mother-to-infant transmission of HBV and
their decisions on how to feed their infants [17,54]. In
our meta analysis, reference search, data extraction and
q u a l i t ye v a l u a t i o nw e r ed o n eb yt w oi n d e p e n d e n t
Table 2 Proportion of the mothers with high infectivity overall, by language and quality of papers
Groups Breastfeeding Formula feeding
No of high infectivity/
Total No
Proportion of
high infectivity (%)
No of high infectivity/
Total No
Proportion of
high infectivity (%)
All studies 739/2001 36.9 812/1843 44.1
Language of papers
English 29/90 32. 2 60/239 25.1
Chinese 710/1911 37.2 752/1604 46.9
Quality of papers
high 37/109 33.9 71/212 33.5
low 702/1892 37.1 741/1631 45.4
CHB: chronic hepatitis B infection
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Page 7 of 10Figure 2 Effect of breastfeeding on occurrence of chronic hepatitis B (CHB) infection among the infants born of CHB mothers with
high and low HBV infectivity analyzed by a random-effects model. RD: risk difference; CI: confidence interval; CHB: chronic hepatitis B.
Figure 3 The Egger’s funnel plot with pseudo 95% confidence
limits for the 32 studies on the effect of breastfeeding on
occurrence of chronic hepatitis B (CHB) infection among the
infants born of CHB mothers. RD: risk difference; CI: confidence
interval; CHB: chronic hepatitis B. The circles alone and enclosed
with square represented respectively the included and filled studies.
Figure 4 The Egger’s funnel plot with pseudo 95% confidence
limits for the 16 studies on the effect of breastfeeding on
occurrence of chronic hepatitis B (CHB) infection among the
infants born of CHB mothers with high and low infectivity. RD:
risk difference; CI: confidence interval; CHB: chronic hepatitis B. The
circles alone and enclosed with square represented respectively the
included and filled studies.
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Page 8 of 10investigators and examined by the third one before a
consensus was reached, thus the completeness and
appropriateness of the studies included for analysis were
ensured. We used RD instead of OR or risk ratio (RR)
as effect measure, which ensured that a reasonable esti-
mation of effect measurement remained untouched and
the 2
nd shortcoming mentioned above was overcome
simultaneously.
Our findings have important implications for current
clinical practice about breastfeeding by CHB mothers,
even with high infectivity. Routine hepatitis B vaccina-
tion allows the infant to enjoy breastfeeding, the nutri-
tional, immunological and psychological advantages of
which are well known[4]. And breastfeeding would also
greatly benefit the mother[4], especially in weakening or
eliminating her fear and guilt which occur often. Unfor-
tunately, contrary to our findings that risk of breastfed
transmission of infantile CHB infection simply does not
exist, the current clinical practices seem discouraging:
(1) any breastfeeding rate is about 30% lower for those
mothers with than without CHB [54], and even lower
(5.4% only) for those with high infectivity [55]; (2) there
is still 25%-50% of the medical professionals did not
recommend infantile breastfeeding by CHB mothers
[15,16]. Thus, health education of breastfeeding with
correct knowledge, attitude and behaviour on the deci-
sion makers, such as medical professional and CHB
mothers, seems to be urgent, especially in those epi-
demic countries, like China.
This meta analysis demonstrates no association
between breastfeeding and risk of infantile CHB infec-
tion from a CHB mother to her infant. Two alternative
explanations must be considered. First, a systematic
bias may be present in follow-up studies arising from
differential lost to follow-up, which has not been men-
tioned in most of the studies. Second, the studied
population varies from study to study, and some
unknown confounders may not be effectively evaluated.
Further evaluation of the effect of breastfeeding from
an HBV infected mother and infantile CHB infection
while taking into consideration of potential biases can
be feasibly achieved with more large-scale prospective
follow-up studies.
Conclusions
Breast milk is infectious; yet, breastfeeding, even by
mothers with high infectivity, is not associated with
demonstrable risk of infection of infantile CHB. This
may be partly because infection mainly occurs during
delivery and the protection by vaccination. The finding
concurs with that of individual studies and supports the
WHO recommendation of BF, irrespective of the HBV
status of the mothers.
Additional material
Additional file 1: Figure S1 Flow chart for the process of retrieving
papers in our meta analysis. CBM: Chinese BioMedical Literature
database, CNKI: Chinese National Knowledge Infrastructure.
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